Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Adaptimmune Ther Ads (NQ: ADAP )

4.180 USD +0.150 (+3.72%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 17, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,385,990
Open 4.000
Bid (Size) 4.180 (1)
Ask (Size) 4.280 (3)
Prev. Close 4.030
Today's Range 3.930 - 4.220
52wk Range 3.790 - 10.93
Shares Outstanding 932,984,520
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune’s Phase 2 SPEARHEAD-1 Trial
From GlobeNewswire News Releases
First Preclinical Data from Adaptimmune’s Mesothelin HiT Program at ASGCT Demonstrate Antigen-specific Tumor Cell Killing in vitro and Complete Tumor Regression in an Animal Model
From GlobeNewswire News Releases

Performance

YTD
-30.45%
-30.45%
1 Month
-18.36%
-18.36%
3 Month
-19.62%
-19.62%
6 Month
-4.57%
-4.57%
1 Year
-58.37%
-58.37%

More News

Read More
Oversold Conditions For Adaptimmune Therapeutics
Tags Stocks
From Market News Video
Analysts Forecast 16% Upside For MOON
Tags ETFs
From ETF Channel
Adaptimmune Reports First Quarter Financial Results and Business Update
From GlobeNewswire News Releases
Interesting ADAP Put And Call Options For July 16th
Tags Stocks
From Market News Video
Thinking about buying stock in Oncternal Therapeutics, Polarityte, Adaptimmune Therapeutics, Oncolytics Biotech, or Precipio?
From PR Newswire
Why Adaptimmune Therapeutics Crushed the Market Today
Tags ADAP Market News
From Motley Fool
Adaptimmune's Stock Trades Higher As TCR Therapy Shows Initial Durability In Soft Tissue Cancer Settings
Tags Trading Ideas Market News Health Care
From Benzinga
MOON's Holdings Could Mean 45% Gain Potential
Tags ETFs
From ETF Channel
Adaptimmune's HiT Program Can Potentially Kill Human Tumor Cells, Animal Study Shows
Tags Small Cap Biotech cancer
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.